ABOUT US
Cellicon Lab is a bio-venture company specialized in peptide development for cosmetics and biological drugs.
In the meantime, we have developed 50 novel peptides as an active-compounds, registered about 45 peptides in PCPC and 22 patents.
From the 2021, we developed DermiShuttle that is a proprietary peptide-based technology and it enables delivery of active compounds to dermis by topical-treatment.
In the meantime, we have developed 50 novel peptides as an active-compounds, registered about 45 peptides in PCPC and 22 patents.
From the 2021, we developed DermiShuttle that is a proprietary peptide-based technology and it enables delivery of active compounds to dermis by topical-treatment.
Min-gyu Soung, PhD
CEO, Founder
After acquiring a Ph.D. in organic chemistry at the University of Tokyo and post doctor in Pacific Northwest Research Institute (Washington, USA). He has focused on researching the development of new peptide drugs for more than 20 years and is focusing on developing peptides that improve problematic skin after the establishment of Cellicon Lab Inc.